Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC682 in ER+/HER2- Advanced Breast Cancer
NCT05489679Phase 1Terminated
- Sponsor
- Accutar Biotechnology, Inc.
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AC0682 in breast cancer, sponsored by Accutar Biotechnology, Inc. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days and Incidence of Treatment Emergent Adverse Events at 24 months. Started Oct 2022; status: terminated.
02
Drugs
AC0682
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05489679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489679.